Drugs / Xiapex
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Xiapex | — | 2011-02-28 | europa.eu ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01229436 | Dec 2010 → Oct 2012 | palmar fibromatosis | Pfizer | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 4 | NCT02476461 Comparator | Apr 2015 → Apr 2016 | palmar fibromatosis | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02647619 Comparator | Oct 2013 → Apr 2022 | palmar fibromatosis | University Hospital, Akershus | Completed | No outcome recorded |
| — | NCT01538017 Comparator | Feb 2012 → Oct 2016 | palmar fibromatosis | Jeppe Lange, MD | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xiapex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01538017 ↗ |
| Route | Other | “injection to cord over joint” NCT01229436 ↗ |